vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»vsp-1481Research ArticleОБЗОРЫ ЛИТЕРАТУРЫLITERATURE REVIEWПЕРСПЕКТИВЫ ПРИМЕНЕНИЯ АДАЛИМУМАБА В ТЕРАПИИ ЮВЕНИЛЬНОГО РЕВМАТОИДНОГО АРТРИТАPROSPECT IN TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS WITH ADALIMUMABАлексееваЕ.И.AlexeevaE.I.БзароваТ.М.BzarovaT.М.ВалиеваС.И.ValievaS.I.ДенисоваР.В.DenisovaR.V.Научный центр здоровья детей РАМН, МоскваРоссияScientific Center of Children's Health, Russian Academy of Medical Sciences, MoscowRussian Federation20080611201576Вопросы современной педиатрии5459Copyright © Алексеева Е., Бзарова Т., Валиева С., Денисова Р., 20082008Алексеева Е., Бзарова Т., Валиева С., Денисова Р.Alexeeva E., Bzarova T., Valieva S., Denisova R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/1481ReferencesFeldman M., Brennan P., Maini R. Role of cytokines in rheumatoid arthritis. Ann. Rev. Immunol. 1996; 14: 397–440.Feldman M., Brennan P., Maini R. Role of cytokines in rheumatoid arthritis. Ann. Rev. Immunol. 1996; 14: 397–440.Beutler B. The rote of tumor necrosis factor in health and disease. J. Rheumatol. 1999; 26 (Suppl. 57): 16–21.Beutler B. The rote of tumor necrosis factor in health and disease. J. Rheumatol. 1999; 26 (Suppl. 57): 16–21.Bazzoni F., Beulier B. Tumor necrosis factor ligand and receptor families. N. Engl. J. Med. 1996; 334: 1717–1725.Bazzoni F., Beulier B. Tumor necrosis factor ligand and receptor families. N. Engl. J. Med. 1996; 334: 1717–1725.Насонов Е.Л. Фактор некроза опухоли–ᾳ — новая мишень для противовоспалительной терапии ревматоидного артрита. Российский медицинский журнал. 2000; 8 (17): 718.Насонов Е.Л. Фактор некроза опухоли–ᾳ — новая мишень для противовоспалительной терапии ревматоидного артрита. Российский медицинский журнал. 2000; 8 (17): 718.Furst D.E., Schiff M.H., Fleischmann R.M. et al. Adahmumab, a fully human anti tumor necrosis factor a monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis results of STAR (Safety Trial of Adahmumab in Rheumatoid Arthritis). J. Rheumatol. 2003; 30: 2563–2571.Furst D.E., Schiff M.H., Fleischmann R.M. et al. Adahmumab, a fully human anti tumor necrosis factor a monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis results of STAR (Safety Trial of Adahmumab in Rheumatoid Arthritis). J. Rheumatol. 2003; 30: 2563–2571.Weinblatt M.E., Keystone E.C., Furst D.E. et al. Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate the ARMADA trial [published erratum appears in Arthritis Rheum 2003,48 855]. Arthritis Rheum. 2003; 48: 35–45.Weinblatt M.E., Keystone E.C., Furst D.E. et al. Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate the ARMADA trial [published erratum appears in Arthritis Rheum 2003,48 855]. Arthritis Rheum. 2003; 48: 35–45.Keystone E.C., Kavanaugh A.F., Sharp J.T. et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy a randomized, placebo controlled, 52 week trial. Arthritis Rheum. 2004; 50: 1400–1411.Keystone E.C., Kavanaugh A.F., Sharp J.T. et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy a randomized, placebo controlled, 52 week trial. Arthritis Rheum. 2004; 50: 1400–1411.Van de Putte L.B., Atkins C., Malaise M. et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann. Rheum. Dis. 2004; 63: 508–516.Van de Putte L.B., Atkins C., Malaise M. et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann. Rheum. Dis. 2004; 63: 508–516.Mease P.J., Gladman D.D., Ritchhn C.T. et al. Adalimumab for the treatment of patients with moderately to severely active psoratic arthritis results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005; 52: 3279–3289.Mease P.J., Gladman D.D., Ritchhn C.T. et al. Adalimumab for the treatment of patients with moderately to severely active psoratic arthritis results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005; 52: 3279–3289.Lipsky P.E., van der Heijde D., St. Clair E.W. et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N. Engl. J. Med. 2000; 343: 1594–1602.Lipsky P.E., van der Heijde D., St. Clair E.W. et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N. Engl. J. Med. 2000; 343: 1594–1602.Moreland L.W., Cohen S.B., Baumgartner S.W., Tindall E.A., Bulpitt K., Martin R. et al Long term safety and efficacy of etanercept in patients with rheumatoid arthritis. J. Rheumatol. 2001; 28: 1238–1244.Moreland L.W., Cohen S.B., Baumgartner S.W., Tindall E.A., Bulpitt K., Martin R. et al Long term safety and efficacy of etanercept in patients with rheumatoid arthritis. J. Rheumatol. 2001; 28: 1238–1244.Breedveld F.C., Weisman M.H., Kavanaugh A.F. et al. The PREMIER study a multicenter, randomized, double blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006; 54: 26–37.Breedveld F.C., Weisman M.H., Kavanaugh A.F. et al. The PREMIER study a multicenter, randomized, double blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006; 54: 26–37.Burmester G.R., Manette X., Montecucco C.M. et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann. Rheum. Dis. Published Online First 20 March 2007. doi: 10 1136/ard. 2006 066761.Burmester G.R., Manette X., Montecucco C.M. et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann. Rheum. Dis. Published Online First 20 March 2007. doi: 10 1136/ard. 2006 066761.Bombardieri S., Ruiz A.A., Fardellone P. et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF antagonist therapy in clinical practice. Rheumatology Advance Access. Published May 15, 2007. doi:10.1093/rheumatology/kem091Bombardieri S., Ruiz A.A., Fardellone P. et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF antagonist therapy in clinical practice. Rheumatology Advance Access. Published May 15, 2007. doi:10.1093/rheumatology/kem091Nicas S.N., Voulgan P.V., Alamanos Y. et al. Efficacy and safety of switching from Infliximab to adalimumab a comparative controlled study. Ann. Rheum. Dis. 2006; 65: 257–260.Nicas S.N., Voulgan P.V., Alamanos Y. et al. Efficacy and safety of switching from Infliximab to adalimumab a comparative controlled study. Ann. Rheum. Dis. 2006; 65: 257–260.Bennett A.N., Peterson P., Zain A. et al. Adalimumab in clinical practice Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure. Rheumatology. 2005; 44: 1026–1031.Bennett A.N., Peterson P., Zain A. et al. Adalimumab in clinical practice Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure. Rheumatology. 2005; 44: 1026–1031.Bijl A.E., Breedveld F.C., Antoni C.E. et al. Adalimumab (HUMIRA») is effective in treating patients with rheumatoid arthritis who previously failed infliximab [abstract SAT0062]. Ann. Rheum. Dis. 2005; 64 (Suppl III): 428.Bijl A.E., Breedveld F.C., Antoni C.E. et al. Adalimumab (HUMIRA») is effective in treating patients with rheumatoid arthritis who previously failed infliximab [abstract SAT0062]. Ann. Rheum. Dis. 2005; 64 (Suppl III): 428.Wick M.C., Ernestam S., Lmdblad S. et al. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel) results from the STURE registry at Karohnska University Hospital. Scand. J. Rheumatol. 2005; 34: 353-358.Wick M.C., Ernestam S., Lmdblad S. et al. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel) results from the STURE registry at Karohnska University Hospital. Scand. J. Rheumatol. 2005; 34: 353-358.Brocq O., Albert C., Roux C. et al. Adalimumab in rheumatoid arthritis after failed infliximab and/or etanercept therapy experience with 18 patients. Joint Bone Spine. 2004; 71: 601-603.Brocq O., Albert C., Roux C. et al. Adalimumab in rheumatoid arthritis after failed infliximab and/or etanercept therapy experience with 18 patients. Joint Bone Spine. 2004; 71: 601-603.Haibel H., Rudwaleit M., Listing J. et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double blind, placebo controlled trial followed by an open label extension up to week fifty-two. Arthritis Rheum. 2008; 58 (7): 1981–1991.Haibel H., Rudwaleit M., Listing J. et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double blind, placebo controlled trial followed by an open label extension up to week fifty-two. Arthritis Rheum. 2008; 58 (7): 1981–1991.Wijbrandts C.A., Klaasen R., Dijkgraaf M.G. еt al. Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss? Ann. Rheum. Dis. Online First published on April 13, 2008 as 10.1136/ard.2008.091611.Wijbrandts C.A., Klaasen R., Dijkgraaf M.G. еt al. Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss? Ann. Rheum. Dis. Online First published on April 13, 2008 as 10.1136/ard.2008.091611.Bijl A.E., Breedveld F.C., Antoni C.E. et al. An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status. Clin. Rheumatol. 2008; 27 (8): 1021–1028.Bijl A.E., Breedveld F.C., Antoni C.E. et al. An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status. Clin. Rheumatol. 2008; 27 (8): 1021–1028.Kimel M., Cifaldi M., Chen N. et al. Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA. J. Rheumatol. 2008; 35 (2): 206–215.Kimel M., Cifaldi M., Chen N. et al. Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA. J. Rheumatol. 2008; 35 (2): 206–215.Лучихина Е.Л., Каратеев Д.Е., Насонов Е.Л. Первый опыт применения адалимумаба в России: предварительные результаты 24 недельного открытого исследования. Научно–практическая ревматология. 2008; 5: 102–106.Лучихина Е.Л., Каратеев Д.Е., Насонов Е.Л. Первый опыт применения адалимумаба в России: предварительные результаты 24 недельного открытого исследования. Научно–практическая ревматология. 2008; 5: 102–106.Ruperto N., Lovell D.J., Goodman S. et al. Long-term efficacy and safety of adalimumab in children with juvenile rheumatoid arthritis (JRA). Data over two years of treatment in a phase III study. Abstract presented at: 8th Annual European League Against Rheumatism (EULAR 2007). June 13–16, 2007. Barcelona, Spain. Abstract THU0195.Ruperto N., Lovell D.J., Goodman S. et al. Long-term efficacy and safety of adalimumab in children with juvenile rheumatoid arthritis (JRA). Data over two years of treatment in a phase III study. Abstract presented at: 8th Annual European League Against Rheumatism (EULAR 2007). June 13–16, 2007. Barcelona, Spain. Abstract THU0195.Dana M.R., Merayo–Lloves J., Schaumberg D.A. et al. VisualDana M.R., Merayo–Lloves J., Schaumberg D.A. et al. Visualoutcomes prognosticators in juvenile rheumatoid arthritis associated uveitis.outcomes prognosticators in juvenile rheumatoid arthritis associated uveitis.Ophthalmology. 1997; 104: 236–244.Ophthalmology. 1997; 104: 236–244.Foster C.S. Diagnosis and treatment of juvenile idiopathic arthritisFoster C.S. Diagnosis and treatment of juvenile idiopathic arthritisassociated uveitis. Current Opin. Ophthalmol. 2003; 14: 395–398.associated uveitis. Current Opin. Ophthalmol. 2003; 14: 395–398.BenEzra D, Cohen E, Maftzir G. Uveitis in children and adolescents. Br. J. Ophthalmol. 2006; 89: 444–448.BenEzra D, Cohen E, Maftzir G. Uveitis in children and adolescents. Br. J. Ophthalmol. 2006; 89: 444–448.Tynjala P., Kotaniemi K., Lindahl P. et al. Adalimumab in the treatment of Juvenile Idiopathic Arthritis associated Uveitis – A Pilot Study. Abstract presented at: 8th Annual European League Against Rheumatism (EULAR 2007). June 13–16, 2007. Barcelona, Spain. Abstract THU0483.Tynjala P., Kotaniemi K., Lindahl P. et al. Adalimumab in the treatment of Juvenile Idiopathic Arthritis associated Uveitis – A Pilot Study. Abstract presented at: 8th Annual European League Against Rheumatism (EULAR 2007). June 13–16, 2007. Barcelona, Spain. Abstract THU0483.Vazquez–Cobian B., Flynn Т., Lehman A. Adalimumab therapy for childhood uveitis. J. Pediatr. 2006; 149: 572–575.Vazquez–Cobian B., Flynn Т., Lehman A. Adalimumab therapy for childhood uveitis. J. Pediatr. 2006; 149: 572–575.Tynjälä P., Kotaniemi K., Lindahl P. et al. Adalimumab in juvenile idiopathic arthritis associated chronic anterior uveitis. Rheumatology. 2008; 47 (3): 339–344.Tynjälä P., Kotaniemi K., Lindahl P. et al. Adalimumab in juvenile idiopathic arthritis associated chronic anterior uveitis. Rheumatology. 2008; 47 (3): 339–344.Biester S., Deuter C., Michels H. et al. Adalimumab in the therapy of uveitis in childhood. Br. J. Ophthalmol. 2007; 91 (3): 274–276.Biester S., Deuter C., Michels H. et al. Adalimumab in the therapy of uveitis in childhood. Br. J. Ophthalmol. 2007; 91 (3): 274–276.Heiligenhaus A., Horneff G., Greiner K. et al. Inhibitors of tumour necrosis factor-alpha for the treatment of arthritis and uveitis in childhood. Klin. Monatsbl. Augenheilkd. 2007; 224 (6): 526-531Heiligenhaus A., Horneff G., Greiner K. et al. Inhibitors of tumour necrosis factor-alpha for the treatment of arthritis and uveitis in childhood. Klin. Monatsbl. Augenheilkd. 2007; 224 (6): 526-531Foeldvari I., Nielsen S., Kümmerle–Deschner J. et al. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis associated uveitis refractory to second line agents: results of a multinational survey. Nat. Clin. Pract. Rheumatol. 2007; 3 (11): 608–609.Foeldvari I., Nielsen S., Kümmerle–Deschner J. et al. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis associated uveitis refractory to second line agents: results of a multinational survey. Nat. Clin. Pract. Rheumatol. 2007; 3 (11): 608–609.Лисицин А.О., Алексеева Е.И., Бзарова Т.М. и др. Опыт применения адалимумаба у больной юношеским полиартритом с поражением глаз. Вопросы современной педиатрии. 2008; 7 (5): 115.Лисицин А.О., Алексеева Е.И., Бзарова Т.М. и др. Опыт применения адалимумаба у больной юношеским полиартритом с поражением глаз. Вопросы современной педиатрии. 2008; 7 (5): 115.
The authors declare that there are no conflicts of interest present.